Related Experiment Video
Updated: Aug 9, 2026
An Economical and Versatile High-Throughput Protein Purification System Using a Multi-Column Plate Adapter
Published on: May 21, 2021
Process scale-up studies for protein C separation using IMAC
Insights
Protein C (PC) deficiency causes thrombosis. A new purification method using ion-exchange chromatography and IMAC IDA-Cu efficiently recovers active PC from Cohn fraction IV-1 for treating patients.
Area of Science:
- Biochemistry
- Hematology
- Biotechnology
Background:
- Protein C (PC) is a critical anticoagulant regulating blood hemostasis.
- PC deficiency leads to thrombosis, impairing oxygen transport and causing conditions like deep vein thrombosis (DVT).
- Existing treatments for PC deficiency carry risks of bleeding and other complications.
Purpose of the Study:
- To develop an efficient and scalable method for purifying active Protein C (PC).
- To produce large quantities of low-cost PC from Cohn fraction IV-1 for therapeutic use.
- To investigate a combined purification strategy for enhanced PC recovery.
Main Methods:
- Utilized a combination of ion-exchange chromatography and Immobilized Metal Affinity Chromatography (IMAC) with IDA-Cu.
- Applied the method for large-scale separation of PC from Cohn fraction IV-1.
- Focused on optimizing recovery of active PC.
Main Results:
- Achieved significant recovery of active Protein C (PC) using the developed purification process.
- The combined chromatography method demonstrated effectiveness for large-scale PC separation.
- Recovered approximately half of the active PC from the starting material.
Conclusions:
- The developed purification process offers a viable method for large-scale, cost-effective production of Protein C (PC).
- This method holds promise for treating patients with Protein C deficiency.
- Future work will focus on verifying the scalability of the IMAC column.
Abstract:
Protein C (PC) is the pivotal anticoagulant and antithrombotic in the human coagulation cascade. PC deficiency can disturb the blood hemostasis and cause thrombosis, inhibiting oxygen transport to tissue, and resulting in major medical problems such as deep vein thrombosis (DVT). The current treatment can cause bleeding and other major medical problems. PC circulates in the blood as a zymogen and is only activated when and where it is needed. PC is a safe anticoagulant without harmful side effects. A combination of ion-exchange chromatography and IMAC IDA-Cu was studied for the relatively large scaled PC separation from Cohn fraction IV-1. Almost half of the active PC was recovered by using this process. In future work, we will verify the linearity of the IMAC column scale-up. This process can be used to produce PC from Cohn fraction IV-1 at large quantities and low cost to treat PC-deficient patients.
